Regulation of Dopamine Transporter Function and Cell Surface Expression by D3 Dopamine Receptors*

  1. Agustin Zapata1,
  2. Bronwyn Kivell1,
  3. Yang Han§,
  4. Jonathan A. Javitch§,
  5. Elizabeth A. Bolan,
  6. David Kuraguntla,
  7. Vanaja Jaligam,
  8. Murat Oz,
  9. Lankupalle D. Jayanthi,
  10. Devadoss J. Samuvel,
  11. Sammanda Ramamoorthy2 and
  12. Toni S. Shippenberg23
  1. Integrative Neuroscience Section, National Institutes of Health/National Institute on Drug Abuse Intramural Research Program/Department of Health and Human Services, Baltimore, Maryland 21224, the §Departments of Psychiatry and Pharmacology, Center for Molecular Recognition, College of Physicians and Surgeons, Columbia University, New York, New York 10032, and the Department of Neurosciences, Division of Neuroscience Research, Medical University of South Carolina, Charleston, South Carolina 29425
  1. 3 To whom correspondence should be addressed: Integrative Neuroscience Section, NIDA, 5500 Nathan Shock Dr., Baltimore, MD 21224. Tel.: 410-550-1514; E-mail: tshippen{at}intra.nida.nih.gov.

Abstract

D3 dopamine receptors are expressed by dopamine neurons and are implicated in the modulation of presynaptic dopamine neurotransmission. The mechanisms underlying this modulation remain ill defined. The dopamine transporter, which terminates dopamine transmission via reuptake of released neurotransmitter, is regulated by receptor- and second messenger-linked signaling pathways. Whether D3 receptors regulate dopamine transporter function is unknown. We addressed this issue using a fluorescent imaging technique that permits real time quantification of dopamine transporter function in living single cells. Accumulation of the fluorescent dopamine transporter substrate trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium (ASP+) in human embryonic kidney cells expressing human dopamine transporter was saturable and temperature-dependent. In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP+ uptake. Similar agonist effects were observed in Neuro2A cells and replicated in human embryonic kidney cells using a radioligand uptake assay in which binding to and activation of D3 receptors by [3H]dopamine was prevented. D3 receptor stimulation activated phosphoinositide 3-kinase and MAPK. Inhibition of either kinase prevented the quinpirole-induced increase in uptake. D3 receptor activation differentially affected dopamine transporter function and subcellular distribution depending on the duration of agonist exposure. Biotinylation experiments revealed that the rapid increase of uptake was associated with increased cell surface and decreased intracellular expression and increased dopamine transporter exocytosis. In contrast, prolonged agonist exposure reduced uptake and transporter cell surface expression. These results demonstrate that D3 receptors regulate dopamine transporter function and identify a novel mechanism by which D3 receptors regulate extracellular dopamine concentrations.

Footnotes

  • 4 The abbreviations used are: DA, dopamine; DAT, DA transporter; ANOVA, analysis of variance; ELISA, enzyme-linked immunosorbent assay; PKC, protein kinase C; MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinase; DMEM, Dulbecco's modified Eagle's medium; BSA, bovine serum albumin; PBS, phosphate-buffered saline; MesNa, sodium 2-mercaptoethanesulfonate; TfR, transferrin receptor; h, human; ASP+, trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium; YFP, yellow fluorescent protein; GFP, green fluorescent protein; df, degrees of freedom; MEK, MAPK/ERK kinase.

  • 5 N. Sen and J. A. Javitch, unpublished results.

  • * This work was supported by the National Institutes of Health/National Institute on Drug Abuse (NIDA) Intramural Research Program and National Institute on Drug Abuse and National Institutes of Health Grants P50DA015369, MH062612 (to S. R.), GM081054 (to L. D. J.), MH57324, MH54137, and DA11495 (to J. A. J.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • 1 Both authors contributed equally and should be considered first authors.

  • 2 Both authors contributed equally and should be considered senior authors.

    • Received December 22, 2006.
    • Revision received September 28, 2007.
« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement